A Trial to Compare the Laser Treatment (SLT vs. ALT) in Glaucoma Patients (SLTRepeat)
Glaucoma

About this trial
This is an interventional treatment trial for Glaucoma focused on measuring glaucoma, laser, SLT, ALT
Eligibility Criteria
Inclusion Criteria:
- Over age of 18 yo.
- OAG including pigmentary dispersion syndrome and pseudoexfoliation
- OAG has been treated with 360 degrees of SLT
- two sighted eyes,
- willing to participate after being informed of and reading the patient information material.
Exclusion Criteria:
- Narrow angle glaucoma
- Previous glaucoma surgery
- Eye surgery expected in the next 12 months
- Severe corneal disease
- On or anticipated steroid in 6 months
- Pregnant or breast feeding
Sites / Locations
- Rockyview General Hospital, University of Calgary
- Royal Alexandra Hospital, University of Alberta
- Eye Care Centre, Dalhousie University
- McMaser University, St. Joseph's Healthcare Hamilton, CAHS Regional Eye Institute
- Ivey Eye Institute, St. Joseph's Hospital, Western University
- Sunnybrook Health Sciences Centre, University of Toronto
- McGill University, Dept. of Ophthalmology, Royal Victoria Hospital,
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Argon laser trabeculoplasty
selective laser trabeculoplasty
Up to the year 2005, the vast majority of ophthalmologists used Argon laser trabeculoplasty (ALT) as the mode of laser therapy. ALT is effective but its most significant problem is that its effectiveness decreases with re-treatment since the tissue it targets (the trabecular meshwork) is changed by the laser rendering repeat treatments less effective.
Post 2005, a newer mode of laser therapy, selective laser trabeculoplasty (SLT) has emerged as the standard of care laser. There are many potential advantages to SLT but to date these advantages are only theoretical. The most important potential clinical advantage of SLT is that it causes less damage to the tissue it targets.